Evidence map›Paper›PMID 37236789›Full record

GuidelineClinical medicine (London, England)2023

The diagnosis and treatment of catatonia.

Jonathan P Rogers, Michael S Zandi, Anthony S David

Abstract readPractice Guideline
In one paragraph

Guideline in Clinical medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Genetics of catatonia: a systematic review of case reports and a gene pathway analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Pooled it
  2. Pooled it
  3. Frozen emotions, frozen bodies: a systematic review of limbic system alterations in catatonia.European archives of psychiatry and clinical neuroscience · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Treatment of Catatonia with Benzodiazepine, Electroconvulsive Therapy and Memantine in an Adolescent: a Case Report.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Orbitofrontal sulcal patterns in catatonia.European psychiatry : the journal of the Association of European Psychiatrists · 2023
    Article
  18. Listening to the patient, listening to the data.Clinical medicine (London, England) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan P RogersUniversity College London, London, UK, and specialty registrar in general adult and old age psychiatry, South London and Maudsley NHS Foundation Trust, London, UK jonathan.rogers@ucl.ac.uk.
Michael S ZandiNational Hospital for Neurology and Neurosurgery, London, UK, and honorary associate professor, Queen Square Institute of Neurology, University College London, London, UK.
Anthony S DavidInstitute of Mental Health, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catatonia is a severe neuropsychiatric syndrome that affects emotion, speech, movement and complex behaviour. It can occur in a wide range of psychiatric and neurological conditions, including depression, mania, schizophrenia, autism, autoimmune encephalitis (particularly NMDAR encephalitis), systemic lupus erythematosus, thyroid disease, epilepsy and medication-induced and -withdrawal states. This concise guideline highlights key recommendations from the British Association for Psychopharmacology (BAP) Catatonia Guideline, published in April 2023. Important investigations may include neuroimaging, electroencephalography and assessment for neuronal autoantibodies in serum and cerebrospinal fluid. First-line treatment comprises benzodiazepines and/or electroconvulsive therapy. The benzodiazepine of choice is lorazepam, which is sometimes used in very high doses. Multidisciplinary working between psychiatrists and physicians is often essential. The main limitation of the guidelines is the low quality of the underlying evidence, comprising mainly small observational studies and case reports or series.

Indexed as

CatatoniaElectroconvulsive TherapyNervous System DiseasesBenzodiazepinesHumansSyndromeBenzodiazepinesbenzodiazepinecatatoniacatatonic schizophreniaelectroconvulsive therapyencephalitisguidelineneuroleptic malignant syndrometreatment

Identifiers

PMID37236789
PMCPMC11046566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.